

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Cabotegravir injections for preventing HIV-1 in adults and young people [ID6255]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • ViiV Healthcare (cabotegravir) <p><u>Community organisations</u></p> <ul style="list-style-type: none"> • Africa Advocacy Foundation • African Health Policy Network • Aymara Social Enterprise • Black Health Agency for Equality • George House Trust • GMFA – The Gay Men’s Health Charity • HIV i-Base • LGBT Foundation • NAM • National AIDS Trust • NAZ • Positively UK • Sophia Forum • South Asian Health Action • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust • The Haemophilia Society • The Love Tank • UK-CAB <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association for Clinical Biochemistry and Laboratory Medicine – Microbiology Section • British Association for Psychopharmacology • British Association for Sexual Health and HIV • British Geriatrics Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Haemophilia Wales • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • AAH Pharmaceuticals Ltd (emtricitabine, tenofovir disoproxil) • Accord Healthcare Ltd (emtricitabine, tenofovir disoproxil) • Advanz Pharma (emtricitabine, tenofovir disoproxil) • Alliance Healthcare (Distribution) Ltd (emtricitabine, tenofovir disoproxil) • AmaroX Ltd (emtricitabine, tenofovir disoproxil) • Aristo Pharma Ltd (tenofovir disoproxil) • Aurobindo Pharma (emtricitabine,

Final stakeholder list for the evaluation of Cabotegravir injections for preventing HIV-1 in adults and young people [ID6255]

Issue date: November 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 4

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British HIV Association • British Infection Association • Children's HIV Association (CHIVA) • English HIV and Sexual Health Commissioners Group (EHSMSG) • HIVPA • Infection Prevention Society • Microbiology Society • National HIV Nurses Association • Positive Prevention Plus • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Psychiatrists • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Clinical Virology Network <p><u>Others</u></p> <ul style="list-style-type: none"> • Association of Directors of Public Health (ADPH) • Department of Health and Social Care • NHS England 	<p>tenofovir disoproxil)</p> <ul style="list-style-type: none"> • Dr Reddy's Laboratories (UK) Ltd (emtricitabine, tenofovir disoproxil) • Gilead Sciences Ltd (emtricitabine, tenofovir disoproxil) • Glenmark (emtricitabine, tenofovir disoproxil) • Laurus Generics GmbH (emtricitabine, tenofovir disoproxil) • Lupin Healthcare (UK) Ltd (emtricitabine, tenofovir disoproxil) • Macleods Pharma UK Ltd (emtricitabine, tenofovir disoproxil) • Medihealth (Northern) Ltd (tenofovir disoproxil) • Sandoz Ltd (tenofovir disoproxil) • Teva UK Ltd (emtricitabine, tenofovir disoproxil) • Thornton & Ross Ltd (tenofovir disoproxil) • Tillomed Laboratories Ltd (emtricitabine, tenofovir disoproxil) • Viatrix UK Healthcare Ltd (emtricitabine, tenofovir disoproxil) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Infectious Diseases Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • UCL Centre for Sexual Health & HIV Research • UK National Screening Committee <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

